Conference on Bacteriophages: Biology, Dynamics, and Therapeutics features the newest and most consequential research on scientific advances and future clinical applications of bacteriophages. Abstracts should be original research and are selected based on their scientific significance, timeliness, quality of data and methodology, and adherence to the guidelines described below.
General and Late Decision Abstract Submission Cycles
Late Decision Abstract Submission Deadline is August 13, 2025. Submitting an abstract is straightforward and can be completed independently of registration and payment to attend the conference.
- General Abstract Submission: Meeting the deadline of May 14, 2025, provides the potential to be selected for either an oral or poster presentation and for new investigators to apply for a scholarship. The General Abstract submission cycle is especially recommended for presenters from outside the United States who need to secure a visa.
- Late Decision Abstract Submission: Those who miss the General Abstract deadline may submit a Late Decision abstract by August 13, 2025, to be considered for an oral or poster presentation. For more details, see Key Dates and Deadlines.
Step 1: Create an Account on the Abstract Submission System
The individual submitting the abstract should be one of the listed authors on the abstract. Although not required, we recommend that the presenting author submit the abstract. To begin the submission process, create an account on the Abstract Submission System (button below). An email will be sent from Phages@iasusa.org to confirm your email address and grant you access to the system.
Abstract Submission System
For support, email Phages@iasusa.org
Step 2: Submit Abstract Information (Guidelines and Instructions)
Requirements for Authorship: Authors listed in the abstract should conform to the International Committee of Medical Journal Editors (ICMJE) recommendations for authorship:
- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- Drafting the work or revising it critically for important intellectual content; AND
- Final approval of the version submitted; AND
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
See: ICMJE Defining the Role of Authors and Contributors
Author Listing: Up to 15 authors can be included in each abstract. Listing more than 15 authors will result in the removal of the authors listed last in the author block. Submitters may also include one (1) Research Group that will be included in the author block.
The author submitting an abstract affirms that each of the listed authors has reviewed and approved the contents of the abstract. This affirmation is essential to reflect the accuracy of the data presented and the scientific validity of the results and conclusions. The authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Presenting Author: The author noted as the presenting author on an abstract is responsible for giving the presentation if the abstract is accepted. In an emergency, an alternate may be selected from among the coauthors listed in the abstract. The new presenting author must update the abstract submission to disclose financial relationships with ineligible companies. Contact Phages@iasusa.org with any changes in presenting author.
Posthumous Inclusion of a Coauthor: Presenters may recognize the contributions of a deceased colleague during the presentation at the conference. However, posthumous recognition of a coauthor is not permitted within the listing of authors in the abstract as the deceased author cannot meet the ICJME criteria 3.
The abstract title should be concise and clearly convey the subject of the abstract and is limited to 100 characters including spaces. Titles should be written in Title Case based on the American Medical Association (AMA) style.
AMA style calls for capitalizing all nouns, pronouns, verbs, adverbs, adjectives, prepositions, and conjunctions with more than four letters. Prepositions and coordinating conjunctions with four or fewer letters always remain in lowercase. For hyphenated words, capitalize the first letters of both words only when they are equal, only the first word is capitalized in the case of prefixes and suffixes. When using scientific names in titles, only the first word begins with a capital letter; the second one remains in lowercase. For example, Dracaena trifasciata.
The abstract text is submitted in a single text field of up to 2500 characters, including spaces. The abstract content should address the following:
- Why was the study conducted? Briefly describe the rationale of the study, which can include the hypothesis.
- What was done and how was it done? Detail the experimental methods, statistics, and processes employed in the study.
- What were the findings? Describe the findings of the study, including data. Include any relevant sex stratification and other demographic variables.
- What does the study suggest or imply? Logically describe sound conclusions and reliable inferences drawn from the study results.
During submission, note if the study has been previously published or presented. Text that is under copyright by a publication or another conference should not be submitted verbatim but should be adapted for the Conference on Bacteriophages.
If the data have been previously presented or published, the submitter should indicate what new data, if any, are included in the submission.
One (1) figure, table, or other illustration can be included in an abstract submission if it provides essential detail about the work that the abstract text cannot adequately describe. The table or figure should be legible if printed in a 4” x 4” (10 cm x 10 cm) space.
Each abstract is assigned to the review team whose expertise matches that of the abstract’s subject matter. The abstract is most likely to receive an equitable review if the submitter carefully selects the correct category during submission.
Indicating up to 5 search terms ensures that the presentation will be connected to other presentations with a related subject matter. When adding a term, consider that it should often be a single word or idea. Complex terms should be simplified and entered as separate search terms. Search terms should be entered in the text field and separated by commas.
The person who submits an abstract must affirm the following on behalf of the presenting author and coauthors.
- All coauthors have reviewed and approved the abstract’s content.
- If accepted, the presenting author will present the abstract in the format designated by the Scientific Committee (eg, Oral Abstract or Poster) and will be present for the session(s) to which they are assigned.
- If the designated presenting author cannot present the abstract, a new presenter from among the coauthors listed on the abstract will be selected. The new presenter must provide a disclosure of financial relationships.
- Complete and accurate contact (email) and affiliation information for all coauthors have been provided .
The presentation may be withdrawn from the conference if the above conditions are not met.
The presenting author also affirms that:
- Financial relationships with ineligible (commercial) companies will be disclosed by the presenting author. (Instructions below in Step 3). If the new presenter is designated after disposition, financial disclosures of the new presenting author must be provided .
- Permission is given for the presentation to be videotaped and recorded and the abstract to be published in the Abstract eBook, IAS-USA website, Topics in Antiviral Medicine (for eventual listing in the National Library of Medicine), and other related conference materials.
Each abstract is reviewed and scored independently by experts in the field. The review of abstracts begins immediately after the submission deadline. Therefore, changes to abstracts are not possible after the submission deadline.
The disposition of each abstract will be sent via email to the abstract submitter and all authors listed on the abstract submission. Accurate professional email addresses for the presenting author and all coauthors are required for this purpose.
Step 3: Abstract Accepted – Conference Registration for Authors | Presenting Authors Provide Financial Discloses
Pre-Approval for Registration and Creating an IAS-USA Account
Authors (presenters and coauthors) on abstracts accepted for presentation are pre-approved to register for the Conference. After receiving the abstract disposition email, authors should create an IAS-USA account (or log into an existing account) and finalize their registration, making sure that the email address on the IAS-USA account matches the email address on the accepted abstract. Follow the steps on the Registration – IAS-USA.org page.
Presenting Author Financial Disclosures
Presenting author should Log in or create an IAS-USA profile and access the Financial Disclosure form by clicking their name in the Upper Left of the home page and selecting the Financial Disclosure link in the menu. Disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. If the presenting author already has an IAS-USA account with a financial disclosure, they should review and verify that the disclosure is still accurate. Any actual or apparent conflicts of interest of those parties are resolved and mitigated before the continuing medical education (CME) activity is delivered. The ACCME defines an ineligible company as “those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. A current financial disclosure statement is required of all presenters at the Conference on Bacteriophages.